Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion

Archives of Ophthalmology

Volumn 122, Issue 8, 2004, Pages 1131-1136

  Ip, Michael S ^a,c   Gottlieb, Justin L ^a   Kahana, Alon ^a   Scott, Ingrid U ^b   Altaweel, Michael M ^a   Blodi, Barbara A ^a   Gangnon, Ronald E ^a   Puliafito, Carmen A ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; TRIAMCINOLONE;

ADULT; AGED; CENTRAL RETINA VEIN OCCLUSION; CILIARY DISK; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; IRIS NEOVASCULARIZATION; NEOVASCULARIZATION (PATHOLOGY); OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA EDEMA; REVIEW; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR EDEMA, CYSTOID; MIDDLE AGED; RECURRENCE; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; SAFETY; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 3543147844     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.8.1131     Document Type: Review

References (34)

1. Klein ML, Finkelstein D. Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol. 1989;107:1297-1302.
2. Central Vein Occlusion Study Group. Baseline and early natural history report: the Central Vein Occlusion Study. Arch Ophthalmol. 1993;111:1087-1095.
3. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486-491.
4. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M Report. Ophthalmology. 1995;102:1425-1433.
5. Green WR, Chan CC, Hutchins GM, Terry JM. Central Retinal Vein Occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981;79:371-422.
6. Hockley DJ, Tripathi RC, Ashton N. Experimental branch vein occlusion in rhesus monkeys, III. Br J Ophthalmol. 1979;63:393-411.
7. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997; 46:1473-1480.
8. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. J Biol Chem. 1999;274:23463-23467.
9. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol. 1997;12:99-109.
10. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998; 105:412-416.
11. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315.
12. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol. 1997;16:398-406.
13. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central vein occlusion. Br J Ophthalmol. 2002;86:247-248.
14. Ip MS, Kumar KS. Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol. 2002;120:1217-1219.
15. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240:782-783.
16. Ip MS, Kahana A, Altaweel MA. Treatment of central retinal vein occlusion with triamcinolone acetonide. Semin Ophthalmol. 2003;18:67-73.
17. Hee MR, Puliafito CA, Duker JS, et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology. 1998;105:360-370.
18. Muscat S, Parks S, Kemp E, Keating D. Repeatability and reproducibility of macular thickness measurements with the Humphrey OCT system. Invest Ophthalmol Vis Sci. 2002;43:490-495.
19. McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastamosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol. 1995; 113:456-462.
20. Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ. Radial optic neurotomy for central retinal vein occlusion. Retina. 2001;21:408-415.
21. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol. 1994;118:421-429.
22. Wolf S, Arend O, Bertram B, et al. Hemodilution therapy in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1994;232:33-39,
23. Weiss JN. Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol. 1998;126:142-144.
24. Lit ES, Tsilimbaris M, Gotzaridis E, D'Amico DJ. Lamina puncture: pars plana optic disc surgery for central retinal vein occlusion. Arch Ophthalmol. 2002;120: 495-499.
25. McCuen BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981; 91:785-788.
26. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982;93:415-417.
27. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985;103:1567-1569.
28. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101:190-195.
29. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: a pilot study. Aust N Z J Ophthalmol. 1995;23: 293-298.
30. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor ABL, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26:277-281.
31. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250.
32. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84:1064-1067.
33. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-427.
34. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.